^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
New
Source:
Title:

ATR inhibitor AZD6738 (ceralasertib) exerts antitumor activity as a monotherapy and in combination with chemotherapy and the PARP inhibitor olaparib

Published date:
01/25/2022
Excerpt:
In a BRCA2-mutant patient-derived triple-negative breast cancer (TNBC) xenograft model, complete tumor regression was achieved with 3-5 days of daily AZD6738 per week concurrent with olaparib....These preclinical data provide rationale for clinical evaluation of AZD6738 as a monotherapy or combinatorial agent.
DOI:
10.1158/0008-5472.CAN-21-2997